GlassScriptPhysician profile
John M Hemphill
NPI 1285672329
$2,023,517.63
in general payments reported to CMS, 2019-2025
89 companies · $394K in 2025
The $394K reported for 2025 was more than what 99% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $326K · 2020: $148K · 2021: $223K · 2022: $267K · 2023: $260K · 2024: $405K · 2025: $394K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $571K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $166K · Travel and Lodging: $165K · Consulting Fee: $81K · Honoraria: $44K · Food and Beverage: $33K · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $571,217.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $165,891.25 |
| Travel and Lodging | $164,946.90 |
| Consulting Fee | $80,887.74 |
| Honoraria | $43,702.50 |
| Food and Beverage | $32,502.51 |
| Education | $385.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $312,697.17 | 2019-2025 | |
| Emd Serono, INC. | $264,999.78 | 2019-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $188,970.83 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $172,462.43 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $122,093.44 | 2021-2025 | |
| Horizon Therapeutics Plc | $120,376.52 | 2021-2023 | Uplizna |
| Genzyme Corporation | $113,232.15 | 2019-2025 | |
| Biogen, INC. | $100,608.94 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Argenx US, INC. | $91,094.96 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $84,510.72 | 2019-2022 | |
| Tg Therapeutics, INC. | $66,172.84 | 2021-2025 | Briumvi |
| E.R. Squibb & Sons, L.L.C. | $58,337.45 | 2020-2025 | Zeposia |
| Genentech USA, INC. | $53,886.27 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Celgene Corporation | $43,549.91 | 2019-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $40,095.93 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $36,312.01 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $27,180.74 | 2019-2025 | |
| Impel Pharmaceuticals INC. | $21,032.04 | 2022-2023 | Trudhesa |
| Ucb, INC. | $16,976.74 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Biohaven Pharmaceuticals, INC. | $15,740.97 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $15,070.89 | 2019-2021 | |
| Merz North America, INC. | $13,656.71 | 2019 | |
| Vanda Pharmaceuticals INC. | $10,173.09 | 2024-2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company LTD. | $7,547.82 | 2022 | |
| Pfizer INC. | $7,480.25 | 2019-2025 | |
| Sk Life Science, INC. | $5,515.60 | 2020-2025 | Xcopri |
| Genentech, INC. | $2,505.08 | 2020-2025 | Ocrevus |
| Janssen Scientific Affairs, LLC | $1,362.50 | 2024 | |
| Mallinckrodt Hospital Products INC. | $723.14 | 2020-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $665.39 | 2019-2022 | |
| Sanofi US Services INC. | $621.50 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $519.26 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $505.23 | 2019-2025 | Dysport |
| Kyowa Kirin, INC. | $448.05 | 2019-2023 | Nourianz |
| Neurelis, INC. | $441.02 | 2021-2025 | Valtoco |
| Lilly USA, LLC | $426.22 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Jazz Pharmaceuticals INC. | $416.35 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $389.78 | 2020-2025 | Ingrezza, Ongentys |
| Csl Behring | $356.03 | 2019-2025 | Hizentra |
| Janssen Pharmaceuticals, INC | $323.32 | 2021-2023 | Ponvory |
| Axsome Therapeutics, INC. | $288.57 | 2024-2025 | Symbravo |
| Greenwich Biosciences, INC. | $271.68 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $247.46 | 2021-2025 | Fycompa, Firdapse |
| Acadia Pharmaceuticals INC | $225.64 | 2019-2025 | Daybue |
| Sumitomo Pharma America, INC. | $204.25 | 2023-2024 | Aptiom |
| Janssen Biotech, INC. | $180.61 | 2025 | |
| Scilex Pharmaceuticals INC. | $160.65 | 2023-2025 | Ztlido |
| Merz Pharmaceuticals, LLC | $152.44 | 2021-2025 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $150.35 | 2023-2024 | Rexulti, Nuedexta |
| Acorda Therapeutics, INC | $142.65 | 2019-2023 | Inbrija |
| Avanir Pharmaceuticals, INC. | $136.69 | 2019-2021 | |
| Harmony Biosciences LLC | $136.01 | 2020-2024 | Wakix |
| Mallinckrodt Enterprises LLC | $123.67 | 2019 | |
| Octapharma USA, INC. | $114.98 | 2022-2023 | Panzyga |
| Tanabe Pharma America, INC. | $106.92 | 2020-2024 | |
| Upsher-Smith Laboratories LLC | $99.62 | 2019-2020 | |
| Revance Therapeutics, INC. | $97.94 | 2024-2025 | Daxxify |
| Averitas Pharma INC. | $92.81 | 2023-2025 | Qutenza |
| Grifols USA, LLC | $92.17 | 2023-2025 | Gamunex-C |
| Promius Pharma LLC | $80.03 | 2019 | |
| Hospira, INC. | $71.81 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $70.94 | 2023-2024 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $69.87 | 2024-2025 | Wainua |
| Livanova USA, INC. | $69.46 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alnylam Pharmaceuticals INC. | $64.88 | 2022-2024 | Onpattro, Amvuttra |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $50.79 | 2019-2020 | |
| Boston Scientific Corporation | $49.34 | 2023-2024 | Wolverine Coronary Cutting Balloon, Watchman Flx |
| Aquestive Therapeutics, INC. | $46.21 | 2020-2022 | |
| Assertio Therapeutics, INC. | $42.87 | 2019-2020 | |
| Corium, LLC | $41.80 | 2023 | Adlarity, Azstarys |
| Immedica Pharma US, INC. | $40.49 | 2024-2025 | Ztalmy |
| Sarepta Therapeutics, INC. | $39.31 | 2023 | Exondys 51 |
| Avion Pharmaceuticals | $39.09 | 2022 | |
| Impel Pharmaceuticals LLC | $37.84 | 2025 | Trudhesa |
| Medtronic Vascular, INC. | $25.51 | 2019 | |
| Mdd US Operations, LLC | $24.69 | 2019-2020 | |
| Amylyx Pharmaceuticals, INC. | $23.47 | 2023 | Relyvrio |
| Almatica Pharma LLC | $20.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.83 | 2024 | Hyqvia |
| Bausch Health US, LLC | $20.01 | 2020 | |
| Akcea Therapeutics, INC. | $18.96 | 2020 | |
| Banner Life Sciences, LLC | $18.55 | 2024 | |
| Insightec,INC | $13.72 | 2024 | Exablate |
| Medtronic, INC. | $12.07 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$55,113.18 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hemphill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.